InflaRx N.V. (NASDAQ:IFRX) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of InflaRx N.V. (NASDAQ:IFRX) have been given a consensus rating of “Moderate Buy” by the eight brokerages that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, four have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $7.00.

IFRX has been the subject of a number of analyst reports. Wall Street Zen upgraded InflaRx from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. HC Wainwright raised their target price on InflaRx from $6.00 to $8.00 and gave the company a “buy” rating in a report on Monday, May 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of InflaRx in a research report on Wednesday, June 24th. Zacks Research upgraded InflaRx from a “hold” rating to a “strong-buy” rating in a report on Monday, July 27th. Finally, Cantor Fitzgerald upped their price target on InflaRx from $2.00 to $4.00 and gave the stock an “overweight” rating in a report on Monday, May 11th.

InflaRx Trading Up 2.9%

IFRX opened at $1.75 on Thursday. InflaRx has a 1-year low of $0.74 and a 1-year high of $2.95. The company has a market cap of $126.51 million, a price-to-earnings ratio of -2.46 and a beta of 2.48. The company’s fifty day moving average price is $1.95 and its two-hundred day moving average price is $1.51.

InflaRx (NASDAQ:IFRX) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.08. As a group, equities analysts forecast that InflaRx will post -0.29 earnings per share for the current fiscal year.

Hedge Funds Weigh In On InflaRx

Several hedge funds have recently modified their holdings of the company. ADAR1 Capital Management LLC bought a new position in shares of InflaRx in the first quarter valued at approximately $142,000. XTX Topco Ltd bought a new stake in InflaRx during the fourth quarter worth $135,000. Suvretta Capital Management LLC boosted its position in InflaRx by 22.4% in the fourth quarter. Suvretta Capital Management LLC now owns 7,933,910 shares of the company’s stock worth $8,013,000 after purchasing an additional 1,450,000 shares during the last quarter. Quadrature Capital Ltd bought a new position in InflaRx in the 4th quarter valued at $104,000. Finally, Eversept Partners LP grew its stake in InflaRx by 1.5% in the 4th quarter. Eversept Partners LP now owns 1,757,312 shares of the company’s stock valued at $1,775,000 after purchasing an additional 26,677 shares during the period. Institutional investors own 42.39% of the company’s stock.

InflaRx Company Profile

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.